UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: January 22, 2018
(Date of earliest event reported)
CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
1-36598 |
04-3321804 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
3301 Agriculture Drive, Madison, Wisconsin
53716
(Address of principal executive offices)
(608) 441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| ITEM 7.01 | REGULATION FD DISCLOSURE |
On January 22, 2018, we issued a press release announcing that company management will be participating in Noble Capital Markets' Fourteenth Annual Investor Conference taking place January 29-30, 2018 at the W Hotel, Fort Lauderdale, Florida. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits
| Number | Title | |
| 99.1 | Press release dated January 22, 2018, titled “Cellectar Biosciences to Participate at Noble Capital Markets' Fourteenth Annual Investor Conference” |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: January 22, 2018 | CELLECTAR BIOSCIENCES, INC. | ||
| By: | /s/ John P. Hamill | ||
| Name: John P. Hamill | |||
| Title: Interim Chief Financial Officer | |||
| 3 |
Exhibit 99.1
Cellectar Biosciences to Participate at Noble Capital Markets' Fourteenth Annual Investor Conference
MADISON, Wis., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that company management will be participating in Noble Capital Markets' Fourteenth Annual Investor Conference taking place January 29-30, 2018 at the W Hotel, Fort Lauderdale, Florida. James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview and update on Monday, January 29, 2018 at 1:00 p.m. Eastern time.
Mr. Caruso's presentation will be webcast live at noble.mediasite.com/mediasite/Play/bd87d408fdd34479a0030edf85b4af221d and will be accessible on the Events and Presentations section of the company's website where it will be archived for a period of time.
About Phospholipid Drug Conjugates™
(PDCs™)
Cellectar's product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized phospholipid
ether-drug conjugates (PDCs). The PDCTM platform provides selective delivery of a diverse range of oncologic payloads
to cancerous cells, whether a hematologic cancer or solid tumor, the primary tumor, a metastatic tumor or cancer stem cells. The
selective delivery of oncologic payloads allows for the modification of the payloads' therapeutic window which may maintain or
enhance drug potency while reducing the number and severity of adverse events. The PDC platform takes advantage of a metabolic
pathway utilized by all tumor cell types in all stages of the tumor "cycle." This allows the PDC molecules to gain access
to the intracellular compartment of the tumor cells and for the PDCs to continue to accumulate over time, which enhances drug efficacy.
The PDC platform's mechanism of entry does not rely upon specific cell surface epitopes or antigens as are required by other targeted
delivery platforms. In addition to the benefits provided by the mechanism of entry, PDCs offer the potential advantage of having
the ability to be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered via
the PDC. The PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting
agents.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a biopharmaceutical company
focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company plans to develop
proprietary drugs independently and through research and development (R&D) collaborations. The core drug development strategy
is to leverage our phospholipid drug conjugateTM (PDCsTM) platform to develop oncologic therapeutics that
specifically target treatment to cancer cells. Through R&D collaborations the company's strategy is to generate near-term
capital, supplement internal resources, gain access to novel molecules or payloads, accelerate product candidate development and
broaden our proprietary and partnered product pipelines.
The company's lead therapeutic PDC, CLR 131 is currently being evaluated in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study to assess efficacy in R/R MM and a range of B-cell malignancies. In 2018, the Company plans to initiate a Phase 1 study of CLR 131 for Pediatric Solid Tumors and Lymphoma and a second Phase 1 study of CLR 131 used in combination with external beam radiation for the treatment of Head and Neck Cancer. The companies' proprietary pipeline also includes two pre-clinical chemotherapeutic PDC programs (CLR 1700 and 1900) and partnered assets include PDC's from multiple R&D collaborations.
For more information please visit www.cellectar.com.
Forward-Looking Statement Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate," "continue,"
"plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements
made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development
involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA
review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description
of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange
Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the
date hereof, and we disclaim any obligation to update any such forward-looking statements.
CONTACT:
LHA Investor Relations
Anne Marie Fields
212-828-3777
afields@lhai.com